Results 101 to 110 of about 3,679,356 (272)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience

Clinical Case Reports, 2022
We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%.
Alicia Roldán Pérez, Juan Andrés Vázquez Paganini, M. José Penalva Moreno, Eugenio Giménez Mesa, Alba Sara Vilches Moreno, Claudia Nuñez‐Torrón Stock, Regina Herráez García   +6 more
doaj   +1 more source

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +1 more source

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

Blood Advances, 2022
Steffen Boettcher (University of Zurich and University Hospital Zurich, Switzerland) Roman Schimmer (University of Zurich and University Hospital Zurich, Switzerland) Larisa Kovtonyuk (University of Hospital Zurich and University of Zurich, Switzerland ...
R. Schimmer, Larisa V. Kovtonyuk, N. Klemm, Jonas Fullin, S. Stolz, Jan Mueller, Caiado Francisco, K. Kurppa, B. Ebert, M. Manz, S. Boettcher   +10 more
semanticscholar   +1 more source

Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes [PDF]

Seminars in Oncology, 2011
Hypomethylating agents such as 5-azacytidine or decitabine have been a major breakthrough in the treatment of patients with myelodysplastic syndromes (MDS). They have been shown to improve transfusion requirements and to change the natural history of the disease. However, with increasing cumulative clinical experience, it has become apparent that these
Tapan M, Kadia, Elias, Jabbour, Hagop, Kantarjian   +2 more
openaire   +2 more sources

Differentiation Syndrome and Sweet Syndrome‐Like Overlap Following Venetoclax–Azacytidine and G‐CSF Therapy

JEADV Clinical Practice, EarlyView.
ABSTRACT Differentiation syndrome (DS) and Sweet syndrome (SS) are inflammatory complications mediated by cytokine dysregulation, classically associated with therapies that promote myeloid differentiation or cytokine release. While DS has been primarily linked to all‐trans retinoic acid (ATRA) and IDH inhibitors, recent evidence suggests that ...
Katerina Grafanaki, Maria Gerbesi, Zoe Apalla, Dimitrios Tsokanas, Efstathia Pasmatzi, Alexandros Spyridonidis, Maria Liga   +6 more
wiley   +1 more source

Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes [PDF]

Journal of Clinical Oncology, 2011
Over the last decade, treatment approaches for patients with myelodysplastic syndromes (MDS) have improved significantly. Treatment of MDS is tailored to the specific risk characteristics of the patient. In general, patients are divided into lower- and higher-risk categories.
Guillermo, Garcia-Manero, Pierre, Fenaux
openaire   +2 more sources

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection

Nature Communications, 2019
The development of post-chemotherapy resistance is a significant issue in the management of AML. Here, Caiado et al. suggest that the issue might be circumvented via upfront combination with hypomethylating agents that shape the clonal dynamics and ...
Francisco Caiado, Diogo Maia-Silva, Carolina Jardim, Nina Schmolka, Tânia Carvalho, Cláudia Reforço, Rita Faria, Branka Kolundzija, André E. Simões, Tuncay Baubec, Christopher R. Vakoc, Maria Gomes da Silva, Markus G. Manz, Ton N. Schumacher, Håkan Norell, Bruno Silva-Santos   +15 more
doaj   +1 more source

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia

Clinical Epigenetics, 2021
Background Chronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic malignancy that arises from hematopoietic stem and progenitor cells (HSPCs).
J. Berg, Bianca Perfler, S. Hatzl, Marie-Christina Mayer, Sonja Wurm, B. Uhl, A. Reinisch, I. Klymiuk, S. Tierling, G. Pregartner, G. Bachmaier, A. Berghold, K. Geissler, M. Pichler, G. Hoefler, H. Strobl, A. Wölfler, H. Sill, A. Zebisch   +18 more
semanticscholar   +1 more source

Solamargine induces acute myeloid leukemia differentiation through TLR8 activation

VIEW, EarlyView.
SM, a steroidal alkaloid from Solanum nigrum L. has shown anticancer effect on various kinds of human cancer cells, yet its effect on leukemia cells remains unclear. This study examines antileukemic activities of SM in AML cells. Results indicate SM inhibits growth and promotes apoptosis of AML cells.
Qiaoyan Han, Yuting Chen, Zheyi Li, Yonglin Peng, Zhehan Hu, Yuliang Deng, Yanli Fu, Ming Cheng, Sheng Tan, Jing Tian, Xiaodong Zhao, Miao Sun   +11 more
wiley   +1 more source